Business Context and Reporting Period
Company: Nektar Therapeutics
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: Nektar Therapeutics advances therapeutics through improved drug delivery using three platforms: Advanced PEGylation Technology, Pulmonary Technology, and Supercritical Fluid (SCF) Technology. The company relies heavily on collaborative agreements with pharmaceutical partners, most notably Pfizer for the development of Exubera® (inhaled insulin).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2005 | Nine Months Ended Sep 30, 2005 |
|---|---|---|
| Total Revenue | $36,354 | $93,398 |
| Net Loss | $(23,795) | $(76,872) |
| Loss Per Share (Basic & Diluted) | $(0.28) | $(0.90) |
| Cash and Cash Equivalents | $357,217 | $357,217 (Ending Balance) |
| Short-term Investments | $263,111 | $263,111 (Ending Balance) |
| Total Liquidity (Cash + Investments) | $620,328 | $620,328 |
| Convertible Subordinated Notes | $417,653 | $417,653 |
| Accumulated Deficit | $(793,993) | $(793,993) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 27% for the three-month period and 13% for the nine-month period compared to the same periods in 2004. This was driven by a 69% increase in product and royalty revenue and the introduction of Exubera® commercialization readiness revenue ($4.2M for the quarter).
- Debt Restructuring: In September 2005, the company issued $315.0 million in 3.25% Convertible Subordinated Notes due 2012. Concurrently, it retired approximately $71.3 million of older convertible notes (5% and 3.5% series), resulting in a net increase in total convertible debt from $173.9 million (Dec 31, 2004) to $417.7 million (Sep 30, 2005).
- Operating Expenses: Research and Development (R&D) expenses increased 12% for the quarter and 10% for the nine-month period, primarily due to salary increases and validation testing for Exubera®. General and Administrative (G&A) expenses rose 48% for the quarter, driven by legal fees and compensation.
- Restatement: Prior year figures for 2004 were restated to reclassify approximately $2.9 million (quarter) and $8.4 million (nine-month) from R&D to G&A expenses, and to reclassify debt issuance costs to interest expense.
Guidance, Outlook, and Risks
- Exubera® Status: The FDA extended its review period for Exubera® by three months (to approx. Jan 27, 2006) to review technical chemistry data. The European Medicines Evaluation Agency (EMEA) recommended approval in October 2005. Revenue from Pfizer represented 71% of total revenue for the quarter.
- Acquisition: On October 20, 2005, Nektar completed the acquisition of Aerogen, Inc. for approximately $32 million in cash. A significant portion of the purchase price is expected to be assigned to in-process R&D and expensed in Q4 2005.
- Liquidity Outlook: Management forecasts sufficient cash to meet net operating expense requirements through at least the end of 2007, based on current cash balances of approximately $620 million.
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to the application of accounting policies and insufficient review of financial statements. Disclosure controls were deemed ineffective as of September 30, 2005.
- Legal Proceedings: The University of Alabama (UAH) filed a lawsuit alleging patent infringement and breach of contract regarding licensed technology. Nektar has filed a counter-claim seeking a refund of royalties.
- Accounting Changes: Adoption of SFAS 123R (Stock-Based Compensation) effective Jan 1, 2006, is expected to have a material adverse impact on financial results due to increased compensation expense recognition.
Investor Verification Checklist
- Exubera® Approval Timeline: Verify the final FDA decision date and any potential delays beyond the extended review period, given the company's heavy revenue dependence on Pfizer.
- Debt Maturity Profile: Confirm the ability to service or refinance $102.7 million in convertible notes maturing in 2007 and $315.0 million maturing in 2012.
- Internal Control Remediation: Monitor progress on the remediation plan for the material weakness in financial reporting to ensure future financial statement reliability.
- Aerogen Integration: Assess the impact of the Aerogen acquisition on Q4 2005 earnings, specifically regarding the expensing of in-process R&D assets.
- Legal Exposure: Track the status of the University of Alabama litigation and potential financial exposure from patent royalty disputes.